NCT06632561View on ClinicalTrials.gov

Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

March 9, 2022

Study Completion Date

March 14, 2022

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Empagliflozin 10 mg

Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months

DRUG

Placebo

Sugar pills one tablet daily for 6 months

Trial Locations (1)

62521

Beni-Suef University, BeniSuef

All Listed Sponsors

lead

Ashraf Wasfy Beshay Aziz

OTHER

NCT06632561 - Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus | Biotech Hunter | Biotech Hunter